


Sep 27, 2024



DOI

dx.doi.org/10.17504/protocols.io.kqdg32z31v25/v1

Jorge Machado Alba¹

¹Universidad Tecnologica de Pereira - Audifarma SA

UTP-Audifarma



Jorge Machado Alba

Universidad Tecnologica de Pereira - Audifarma SA

OPEN ACCESS



DOI: dx.doi.org/10.17504/protocols.io.kqdg32z31v25/v1

Protocol Citation: Jorge Machado Alba 2024. Treatment schemes and persistence in Colombian patients diagnosed with inflammatory arthritis after the failure of conventional disease-modifying antirheumatic drugs. **protocols.io**

https://dx.doi.org/10.17504/protocols.io.kqdg32z31v25/v1

License: This is an open access protocol distributed under the terms of the **Creative Commons Attribution License**, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working
We use this protocol and it's
working

Created: September 27, 2024

Last Modified: September 27, 2024

Protocol Integer ID: 108568

Keywords: Disease-Modifying Antirheumatic Drugs; Persistence, Medication; Arthritis, Rheumatoid; Pharmacoepidemiology; Colombia





Funders Acknowledgement:

Grant ID: Contrato No. 2021-263

Disclaimer

This research received funds of Pfizer Colombia



Abstract

Introduction:

Inflammatory arthritis is related to disability, chronic pain, and premature death. A lack of treatment persistence leads to poor control of symptoms, inflammation, and joint damage, thereby worsening quality of life.

Objective: To

determine the effectiveness of antirheumatic drug treatment and the persistence of use in Colombian patients diagnosed with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondyloarthritis (AS), and juvenile rheumatoid arthritis (JIA) after the failure of conventional disease-modifying antirheumatic drugs. (cDMARDs).

Methods: In this retrospective

descriptive study, patients who were diagnosed with RA, PsA, AS, or JIA; were treated at a center specializing in rheumatological diseases; who started their first treatment with biological DMARDs (bDMARDs) or tofacitinib between February 2016 and December 2019; and who were followed up until the discontinuation of treatment or 24 months were evaluated.

Results: A total of 426

patients were included; 78.8% were women, and the mean age was 50.2±14.1 years. The majority had a diagnosis of RA (71.8%). A total of 89.9% had received cDMARDs, and 77.2% had received glucocorticoids. The most frequently initiated bDMARDs were rituximab (31.2%), etanercept (23.0%), and adalimumab (14.6%). A total of 80.3% of patients received concomitant cDMARDs. During an average follow-up of 635.2±189.6 days, 12.9% of patients had changes in their treatment regimen, 26.3% had interruptions in their treatment regimen, and 23.9% discontinued bDMARDs or tofacitinib. Patients who received concomitant cDMARDs were more likely to continue their biological therapy (odds ratio: 8.50; 95% confidence interval: 3.49-20.73; p<0.001).

Conclusions: Follow-up

evaluation of this group of patients revealed that they were treated mainly with non-TNF-α inhibitors associated with cDMARDs, and a low proportion of the patients had changes in therapy, although one-quarter had treatment interruptions or discontinuations.



Attachments



BD GH Colombia Anon....

358KB

